ICON PLC (ICLR) stock
ICLRNasdaqServices-Commercial Physical & Biological Research
$194.65−5.86 (-2.92%)
Close on Nov 13, 2026Market cap $14.90BP/E 33.5Yield –
ICON EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
ICON's EPS for the twelve months ending Sep 30, 2026 was $5.81, up 30.0% year over year. For fiscal 2025 it was $2.90, down 67.4% from the year before. Over ten years it grew -3.1% a year on average. The highest annual figure on record is $8.90 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.90 | -67.4% |
| FY2024 | Dec 31, 2024 | $8.90 | +32.8% |
| FY2023 | Dec 31, 2023 | $6.70 | +9.3% |
| FY2022 | Dec 31, 2022 | $6.13 | +172.4% |
| FY2021 | Dec 31, 2021 | $2.25 | -63.4% |
| FY2020 | Dec 31, 2020 | $6.15 | -9.4% |
| FY2019 | Dec 31, 2019 | $6.79 | +15.3% |
| FY2018 | Dec 31, 2018 | $5.89 | +14.8% |
| FY2017 | Dec 31, 2017 | $5.13 | +10.3% |
| FY2016 | Dec 31, 2016 | $4.65 | +17.1% |
| FY2015 | Dec 31, 2015 | $3.97 | +45.4% |
| FY2014 | Dec 31, 2014 | $2.73 | +65.5% |
| FY2013 | Dec 31, 2013 | $1.65 | +79.3% |
| FY2012 | Dec 31, 2012 | $0.92 | +148.6% |
| FY2011 | Dec 31, 2011 | $0.37 | -74.3% |
| FY2010 | Dec 31, 2010 | $1.44 | -8.3% |
| FY2009 | Dec 31, 2009 | $1.57 | +20.8% |
| FY2008 | Dec 31, 2008 | $1.30 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.58 | – |
| Q2 FY2026 | Jun 30, 2026 | $0.94 | -63.3% |
| Q1 FY2026 | Mar 31, 2026 | $1.36 | -31.7% |
| Q4 FY2025 | Dec 31, 2025 | $1.93 | -46.2% |
| Q3 FY2025 | Sep 30, 2025 | -$3.67 | -243.4% |
| Q2 FY2025 | Jun 30, 2025 | $2.56 | +158.6% |
| Q1 FY2025 | Mar 31, 2025 | $1.99 | +11.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.59 | +61.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.56 | +38.4% |
| Q2 FY2024 | Jun 30, 2024 | $0.99 | -24.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.78 | +34.8% |
| Q4 FY2023 | Dec 31, 2023 | $2.22 | +56.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.85 | -4.6% |
| Q2 FY2023 | Jun 30, 2023 | $1.31 | -7.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.32 | -2.9% |
| Q4 FY2022 | Dec 31, 2022 | $1.42 | – |
| Q3 FY2022 | Sep 30, 2022 | $1.94 | +40.6% |
| Q2 FY2022 | Jun 30, 2022 | $1.41 | -22.5% |
| Q1 FY2022 | Mar 31, 2022 | $1.36 | -28.4% |
| Q3 FY2021 | Sep 30, 2021 | -$1.17 | -168.0% |
| Q2 FY2021 | Jun 30, 2021 | $1.38 | +53.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.82 | +12.3% |
| Q4 FY2020 | Dec 31, 2020 | $1.90 | +8.0% |
| Q3 FY2020 | Sep 30, 2020 | $1.72 | 0.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.90 | -46.7% |
| Q1 FY2020 | Mar 31, 2020 | $1.62 | -0.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.76 | +8.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.72 | +11.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.69 | +29.0% |
| Q1 FY2019 | Mar 31, 2019 | $1.63 | +14.8% |
| Q4 FY2018 | Dec 31, 2018 | $1.62 | +24.6% |
| Q3 FY2018 | Sep 30, 2018 | $1.54 | +14.1% |
| Q2 FY2018 | Jun 30, 2018 | $1.31 | +10.1% |
| Q1 FY2018 | Mar 31, 2018 | $1.42 | +10.1% |
| Q4 FY2017 | Dec 31, 2017 | $1.30 | -1.5% |
| Q3 FY2017 | Sep 30, 2017 | $1.35 | – |
| Q2 FY2017 | Jun 30, 2017 | $1.19 | – |
| Q1 FY2017 | Mar 31, 2017 | $1.29 | – |
| Q4 FY2016 | Dec 31, 2016 | $1.32 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?